BCL2 and ovarian carcinoma: Thus, relative expressions of protein members representing effector phase [Bcl-2, Bik, Bax, Inhibitor of apoptosis (survivin) and execution phase (caspase-7/9, PARP) were evaluated in the treated cells (Figure 5A &5B) (See Additional file 10 (Table S8) for their correlation with ovarian cancer outcomes).